These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8497171)

  • 21. Clinical update on the use of recombinant factor VII.
    Glazer S; Hedner U; Falch JF
    Adv Exp Med Biol; 1995; 386():163-74. PubMed ID: 8851025
    [No Abstract]   [Full Text] [Related]  

  • 22. Recombinant antihemophilic factor.
    Med Lett Drugs Ther; 1993 Jun; 35(898):51-2. PubMed ID: 8497206
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies of cross-reactivity of acquired factor VIII inhibitor activity in hemophilic plasma.
    Abildgaard CF; Vanderheiden J; Lindley A; Rickles F
    Thromb Diath Haemorrh; 1967 Dec; 18(3-4):354-63. PubMed ID: 5590233
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent advances in hemophilia research].
    Ito S
    Rinsho Ketsueki; 1976 Jun; 17(6):580-9. PubMed ID: 787578
    [No Abstract]   [Full Text] [Related]  

  • 26. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-purity factor concentrates in prevention of AIDS.
    Schwarz HP; Kunschak M; Engl W; Eibl J
    Lancet; 1994 Feb; 343(8895):478-9. PubMed ID: 7905970
    [No Abstract]   [Full Text] [Related]  

  • 30. [Consensus hemophilia treatment].
    Briët E; Breederveld C
    Ned Tijdschr Geneeskd; 1987 Oct; 131(43):1914-6. PubMed ID: 3120016
    [No Abstract]   [Full Text] [Related]  

  • 31. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
    Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
    Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemophilia, blood products and AIDS.
    Woodfield DG
    N Z Med J; 1984 Jan; 97(748):51-2. PubMed ID: 6420735
    [No Abstract]   [Full Text] [Related]  

  • 35. A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor VIII inhibitor eradication.
    Goto M; Haga N; Yokota K; Takamizawa K; Takedani H
    Haemophilia; 2016 May; 22(3):e228-31. PubMed ID: 26988340
    [No Abstract]   [Full Text] [Related]  

  • 36. [Preparation of concentrated antihemophilic factor 8 for therapeutic use: the cryoprotein 8].
    Combrisson A; Vergoz D; Champcommunal A; André R
    Transfusion (Paris); 1966; 9(4):303-19. PubMed ID: 5966232
    [No Abstract]   [Full Text] [Related]  

  • 37. FVIII concentrates: old and new.
    Andes WA
    Thromb Res; 1990 Feb; 57(4):673. PubMed ID: 2109372
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV and Canada's hemophiliacs: looking back at a tragedy.
    Dunn K
    CMAJ; 1993 Feb; 148(4):609-12. PubMed ID: 8431823
    [No Abstract]   [Full Text] [Related]  

  • 39. [Patient plaintiffs. No compensation for victims of medication].
    Mulvad N
    Sygeplejersken; 1989 Jan; 89(4):22-4. PubMed ID: 2741046
    [No Abstract]   [Full Text] [Related]  

  • 40. The treatment of hemophilia: past tragedy and future promise.
    Roberts HR
    N Engl J Med; 1989 Oct; 321(17):1188-90. PubMed ID: 2507918
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.